Clinical trials are currently evaluating the response of HNSCC patients to single or dual targeted therapy treatments, such as EGFR (NCT02365662) or PI3K (NCT02145312, NCT02540928) monotherapies or both agents administered in combination (NCT0160231). This evidence concerns the gene PIK3CD and head and neck squamous cell carcinoma.